It’s hard to know how long anxiety disorders will last when you’re in the thick of them. It was during the mid-2000s that my ...

For people with anxiety and depression, these conditions can feel like two sides of the same coin. Researchers are exploring ...

Lexapro (escitalopram) has potential interactions with other medications ... depressive disorder (depression) in adults and certain children. It’s also used to treat generalized anxiety disorder ...

Questions over the extent to which animals can experience mental illness have existed for centuries. Though researchers and ...

Chicago, IL – January 15, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks ...

Acquisition includes CAPLYTA® (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression as an adjunctive and ...

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the ...

Intra-Cellular recently guided to at least $5 billion in peak Caplyta sales. Intra-Cellular’s stock was trading at $127.48, up $32.61, or 34%. J&J’s stock (NYSE:JNJ) was selling for $143.39, up $1.34.

Johnson & Johnson has agreed to acquire Intra-Cellular Therapies for approximately $14.6 billion, in the largest biopharma merger-and-acquisition (M&A) deal announced in two years.

Pharmaceutical giants have recently shown new enthusiasm for mental-health treatments with vast but unrealized promise.

High-functioning anxiety often affects individuals who appear successful and composed but manage anxiety through productivity ...

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic top the list of 15 drugs selected for the second round of ...